Pfizer: Triple Negative Breast Neoplasms trials

The registry lists 18 Triple Negative Breast Neoplasms studies with Pfizer as lead sponsor. 2 are open to participants now and 10 have results posted.

Phase 1 16Phase 2 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid TumorsRecruitingNCT07318805Phase 1
• A Study of PF-08046054/SGN-PDL1V in Advanced Solid TumorsRecruitingNCT05208762Phase 1
• Vaccine-Based Immunotherapy Regimen For NSCLC and TNBCTerminatedNCT03674827Phase 1Results posted
• A Study of PF-06873600 in People With CancerTerminatedNCT03519178Phase 1/2Results posted
• Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast CancerCompletedNCT03310957Phase 1/2Results posted
• PF-06671008 Dose Escalation Study in Advanced Solid TumorsTerminatedNCT02659631Phase 1Results posted
• A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)TerminatedNCT02554812Phase 1/2Results posted
• A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch AlterationsTerminatedNCT02299635Phase 2Results posted
• A Study Of PF-06647020 For Adult Patients With Advanced Solid TumorsCompletedNCT02222922Phase 1Results posted
• A Dose Escalation Study of PF-06650808 in Patients With Advanced Solid TumorsTerminatedNCT02129205Phase 1Results posted
• A Study Of PF-06647263 In Patients With Advanced Solid TumorsTerminatedNCT02078752Phase 1Results posted
• A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)CompletedNCT01920061Phase 1Results posted
• A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid TumorsActive, not recruitingNCT06157892Phase 2
• A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid TumorsTerminatedNCT05194072Phase 1
• A Safety Study of SEA-TGT (SGN-TGT) in Advanced CancerTerminatedNCT04254107Phase 1
• A Safety Study of SGN-LIV1A in Breast Cancer PatientsCompletedNCT01969643Phase 1
• Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor PatientsCompletedNCT01363232Phase 1
• Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor PatientsCompletedNCT01337765Phase 1